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Abstract: mRNA translation requires the ordered assembly of translation initiation factors and
ribosomal subunits on a transcript. Host signaling pathways regulate each step in this process to
match levels of protein synthesis to environmental cues. In response to infection, cells activate
multiple defenses that limit viral protein synthesis, which viruses must counteract to successfully
replicate. Human cytomegalovirus (HCMV) inhibits host defenses that limit viral protein expression
and manipulates host signaling pathways to promote the expression of both host and viral proteins
necessary for virus replication. Here we review key regulatory steps in mRNA translation, and the
strategies used by HCMV to maintain protein synthesis in infected cells.
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1. Introduction
Viruses are completely reliant on the host translation machinery for the synthesis of viral proteins,
since no virus encodes a ribosome. As a result, viral and host mRNAs must compete for access to
ribosomes. Viruses must also counteract host defenses that inactivate the translation machinery after
sensing viral infection. Human cytomegalovirus (HCMV) effectively antagonizes host defenses that
limit viral protein expression. In addition, HCMV manipulates multiple host signaling pathways to
ensure the continued synthesis of both host and viral proteins needed for virus replication. Thus, the
interface between viral mRNAs and the host translation machinery serves as a critical determinant for
successful HCMV infection. The purpose of this review is to summarize key steps in the regulation
of mRNA translation, and strategies by which HCMV manipulates the host translation machinery to
benefit virus replication.
2. The Scanning Model of Translation Initiation
Translation of mRNAs occurs in three steps: initiation, elongation and termination [1,2].
Translation initiation begins with the assembly of the eukaryotic initiation factor 4F (eIF4F) translation
initiation complex on the 7-methyl guanosine cap (m7G cap) at the 5’ end of the mRNA. ([3–5] reviewed
in [2]). The bound eIF4F complex recruits the 43S preinitiation complex (PIC), consisting of the 40S
ribosomal subunit, the ternary complex and multiple initiation factors, to form the 48S initiation
complex. The 48S complex then scans the 5’ untranslated region (UTR) of the mRNA until reaching
the translation start codon, whereupon multiple initiation factors are released and the 60S ribosomal
subunit is recruited [6]. Joining of the 40S and 60S ribosomal subunits to form the 80S ribosome
marks the end of the initiation phase, and the beginning of elongation. Elongation is regulated by
the eukaryotic elongation factor 1 (eEF1), which promotes binding of aminoacyl-tRNAs to the A-site
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of the ribosome, and eukaryotic elongation factor 2 (eEF2), which facilitates the translocation of
peptidyl-tRNA from the A-site to the P-site of the ribosome [7–9]. Peptide elongation continues until a
translation termination codon is encountered, whereupon translation ceases, the nascent peptide chain
is displaced from the ribosome, and the ribosome disassembles [10,11]. The first step of translation,
initiation, is the most regulated step ([12–14] reviewed in [15]) and is described in more detail below.
Formation of the eIF4F complex, which consists of eukaryotic initiation factors 4E (eIF4E),
4G (eIF4G) and 4A (eIF4A), bound to the 5’ m7G cap of an mRNA mediates the initiation of
translation [2,16]. eIF4F assembly begins with binding of eIF4E to the m7G cap [3,17]. After binding
the m7G cap, eIF4E recruits eIF4G, which acts as a scaffold protein that mediates the recruitment of the
eIF4A RNA helicase, completing the assembly of the eIF4F complex [18,19]. eIF4G also coordinates
the interaction of the eIF4F complex with additional factors bound to the mRNA, such as the poly(A)
binding protein (PABP), that enhance translation initiation [2,16,18–20].
Prior to binding the eIF4F complex, multiple initiation factors associate with the 40S ribosomal
subunit to prepare for translation initiation. Together, the 40S subunit and its associated factors are
referred to as the 43S PIC ([21,22] reviewed in [23]). The 43S PIC contains the 40S ribosomal subunit,
multiple initiation factors (e.g., eIF1, eIF1A, eIF3, and eIF5), and a ternary complex composed of the
eukaryotic initiation factor 2 (eIF2), guanosine triphosphate (GTP) and a charged methionyl-tRNA
(tRNAMet) [24]. eIF3 plays a critical role during 43S assembly, acting as a scaffold to recruit multiple
initiation factors to the 40S ribosomal subunit [25]. These factors affect ribosome scanning, eIF4A
helicase activity, and fidelity of start codon recognition once associated with the eIF4F complex on the
5’UTR of the mRNA [25,26].
Recruitment of the 43S PIC to the mRNA is mediated via an interaction between the eIF4G
subunit of the eIF4F complex and eIF3 within the 43S PIC [27]. Together, the 43S PIC, the eIF4F
complex, and the bound mRNA constitute the 48S initiation complex. Once assembled, the 48S
complex scans the 5’UTR of the mRNA until reaching the translation “start” codon [28]. The eIF4A
helicase, whose activity is stimulated by binding to eIF4B [29], unwinds RNA structures that would
otherwise impede 48S scanning [28,30]. Additional RNA helicases such as DDX3, DHX9 and DHX29
also facilitate scanning through areas with high RNA secondary structure [31–34]. Scanning ceases
upon recognition of a translation start site, which almost always consists of an AUG methionine
codon in a favorable sequence context (i.e., Kozak sequence [35]). The combined actions of the eIF1,
eIF1A and eIF5 initiation factors position the tRNAMet over the AUG codon, triggering hydrolysis of
eIF2-bound GTP and release of a subset of initiation factors [6]. eIF5 directs subsequent joining of the
40S and 60S ribosomal subunits to form a functional 80S ribosome, after which peptide elongation
commences [36]. Elongation continues until a translation termination or “stop” codon is encountered,
at which point eukaryotic release factor 1 (eRF-1) together with eukaryotic release factor 3 (eRF-3)
terminates elongation by displacing the nascent peptide from the ribosome [10,11].
3. Alternative Translation Initiation Mechanisms
Translation of some viral mRNAs does not require 40S ribosomal subunit scanning.
Instead, ribosomes are recruited to the site of translation initiation, often with limited or no ribosome
scanning, by specific RNA sequences/structures called internal ribosome entry sites (IRESs) ([37,38]
reviewed in [39]). Ribosome recruitment to IRESs often requires only a subset of translation initiation
factors. For example, translation initiation from the poliovirus IRES is independent of the eIF4E cap
binding protein, but requires eIF4A, eIF4G and the 43S PIC [40]. On the other end of the spectrum,
the cricket paralysis virus (CrPV) IRES requires only 40S and 60S ribosomal subunits to initiate
translation [41,42]. Although these and other IRESs require differing factors to initiate translation,
RNA secondary and tertiary structure is indispensable for the recruitment of ribosomal subunits to
IRES elements [43].
In addition to initiation factors, IRES activity can be enhanced through binding of IRES
trans-activating factors, or ITAFs [44]. Two cellular factors consistently function as ITAFs, the
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polypyrimidine tract binding protein (PTB) and the lupus autoantigen (La). PTB is an RNA binding
protein that directly interacts with RNA secondary structures to promote RNA folding and maintain
IRES structures [45,46]. The La protein binds the 5’UTR of multiple viruses, including poliovirus,
human immunodeficiency virus (HIV), hepatitis C virus (HCV), and influenza virus [47]. Binding of
La to IRES sequences stimulates recruitment of the 40S ribosomal subunit, possibly to promote correct
start codon usage [48]. Both proteins are critical for the activity of multiple viral IRESs ([49,50] reviewed
in [51]) and promote IRES driven translation during HCV, poliovirus and rhinovirus infection [52,53].
4. Signaling Pathways Regulating Translation Initiation
4.1. mTOR Signaling
The target of rapamycin (TOR) kinase is conserved throughout eukaryotes, where it plays
a critical role in modulating protein synthesis in response to the intracellular and extracellular
environment ([54,55] reviewed in [1]). In mammalian cells, mTOR (mammalian TOR) is found in
two complexes: the mTORC1 and mTORC2 complexes [56,57]. While the two complexes share
several subunits, each complex has unique defining components. mTORC1 contains the protein
regulatory-associated protein of mTOR (RAPTOR), while the presence of rapamycin-insensitive
companion of mTOR (RICTOR) defines the mTORC2 complex [58,59]. mTORC1 plays a central
role in regulating translation initiation by controlling the assembly of the eIF4F complex [60]. In the
hypo-phosphorylated state, the eIF4E-binding protein 1 (4EBP1) binds eIF4E and prevents binding
to eIF4G, thereby limiting eIF4F formation [61]. Phosphorylation of 4EBP1 by mTORC1 reduces the
affinity of 4EBP1 for eIF4E, allowing efficient eIF4F complex formation and increasing overall levels of
protein synthesis (Figure 1A) [62].
mTORC1 also promotes protein synthesis by phosphorylating and activating the 70 kDa ribosomal
protein S6 kinase (p70S6K). Active p70S6K phosphorylates several factors involved in translation,
such as eIF4B and eukaryotic elongation factor 2 kinase (eEF2K) [63,64]. When phosphorylated,
eIF4B binds eIF4A and increases its helicase activity, resulting in more efficient 48S scanning through
5’UTRs with significant secondary structure [65]. Like mTORC1 itself, p70S6K also phosphorylates and
deactivates a translation repressor, eEFK2 [64,66]. eEFK2 phosphorylates and inactivates eukaryotic
elongation factor 2 (eEF2), which stimulates the incorporation of amino acids into the growing peptide
chain [67,68]. eEF2K phosphorylation of eEF2 prevents its association with the ribosome, thereby
slowing the rate of elongation [7]. Thus, protein synthesis is induced through multiple mechanisms
upon mTORC1 activation.
Protein synthesis is one of the most energy intensive cellular processes. Therefore mTORC1
is unsurprisingly subject to both positive and negative regulation in response to environmental
cues. This regulation converges on the tuberous sclerosis complex (TSC), which negatively regulates
mTORC1 activity [69,70]. The heterodimeric TSC consists of the tuberous sclerosis 1 (TSC1) and
tuberous sclerosis 2 (TSC2) proteins that together act as a GTPase activating protein (GAP) for the
mTORC1 cofactor Rheb [71]. mTORC1 is activated by association with Rheb-GTP and repressed by
Rheb-GDP. Increased TSC GAP activity stimulates hydrolysis of GTP bound to Rheb, and therefore
inhibits mTORC1 activity [72]. Decreased nutrient availability leads to elevated AMP to ATP ratios
that activate the AMP-regulated protein kinase (AMPK) [73]. Active AMPK phosphorylates TSC2,
stimulating TSC GAP activity and inhibiting mTORC1 activity [74]. Conversely, when nutrients are
plentiful, growth factor receptor signaling activates the phosphoinositide 3-kinase (PI3K), which
phosphorylates and inhibits the TSC complex, thereby promoting mTORC1 activity and eIF4F
assembly [75]. Thus the TSC complex integrates upstream signaling pathways to modulate mTORC1
activity and protein synthesis to match the nutrient availability within the cellular environment.
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(PABP). HCMV also promotes eIF4F assembly by activating mammalian target of rapamycin complex 
1 (mTORC1), which phosphorylates and inhibits the eIF4F antagonist 4EBP1. The HCMV UL38 
protein prevents inactivation of mTORC1 by inhibiting the tuberous sclerosis complex (TSC). pUL38 
also stimulates mTORC1 activity through a TSC2-independent mechanism. mTORC1 activates 
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Recognition of the AUG initiation codon by tRNAMet stimulates the hydrolysis of eIF2-associated 
GTP. The resulting release of the free phosphate triggers eIF2-GDP release from the ribosome [77]. 
Figure 1. Schematic of human cytomegalovirus (HC V) manipulation of translation initiation
and elongation. (A) HCMV stimulates eIF4F formation and activity through multiple mechanisms.
Infection increases levels of eIF4F components (eIF4E, eIF4G, eIF4A) and poly(A) binding protein
(PABP). HCMV also promotes eIF4F assembly by activating mammalian target of rapamycin complex 1
(mTORC1), which phosphorylates and inhibits the eIF4F antagonist 4EBP1. The HCMV UL38 protein
prevents inactivation of mTORC1 by inhibiting the tuberous sclerosis complex (TSC). pUL38 also
stimulates mTORC1 activity through a TSC2-independent mechanism. mTORC1 activates p70S6K,
which phosphorylates eIF4B to increase eIF4A helicase activity. HCMV infection activates the PI3K
pathway to promote mTORC1 activation, and may also regulate translation through activation of MNK
kinases (B) Translation initiation and elongation are maintained during HCMV infection. Inhibition of
eIF2α phosphorylation ensures the regeneration of ternary complexes and continued rounds of
translation initiation. Levels of eEF2 increase during infection through a UL38-dependent mechanism
and may promote translation during HCMV infection.
4.2. eIF2α Kinase Activation
Another focal point in the regulation of translation initiation is the phosphorylation of the
alpha subunit of eukaryotic initiation factor 2 (eIF2α). eIF2α is part of the trimeric eIF2 complex,
which together with GTP and tRNAMet, forms the ternary complex associated with the 43S PIC [76].
Recognition of the AUG initiation codon by tRNAMet s imulates the hydrolysis of eIF2-associated
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GTP. The resulting release of the free phosphate triggers eIF2-GDP release from the ribosome [77].
Eukaryotic initiation factor 2B (eIF2B) exchanges GDP for GTP in the eIF2 complex, allowing
eIF2-GTP to form a new ternary complex and participate in subsequent rounds of initiation [78].
Phosphorylation of eIF2α by one of four eIF2α kinases (see below) greatly increases the affinity of eIF2B
for eIF2, preventing eIF2B release and GTP exchange [79,80]. As eIF2α is present at a much greater
concentration than eIF2B, even small increases in eIF2α phosphorylation can sequester essentially all
of the available eIF2B, preventing the formation of new ternary complexes and resulting in a dramatic
decrease in protein synthesis [81].
Similar to the mTOR signaling pathway, eIF2α kinases regulate protein synthesis in response to
the intracellular environment. Four eIF2α kinases have been identified, each of which are activated
in response to a distinct cellular stress (reviewed in [82]). The heme-regulated inhibitor (HRI) kinase
phosphorylates eIF2α in response to high levels of reactive oxygen species, linking the rate of protein
synthesis to the respiratory capacity of the cell [83]. Accumulation of unfolded proteins within
the endoplasmic reticulum (ER) activates the PKR-like endoplasmic reticulum kinase (PERK) [84],
temporarily inhibiting protein synthesis to allow the cell to properly fold or degrade accumulated
unfolded proteins. The eIF2α kinase general control nonderepressible 2 (GCN2) is activated by binding
to uncharged tRNAs that accumulate during amino acid deprivation, directly linking amino acid
availability to the rate of protein synthesis [85,86]. Especially relevant to viral infections, protein kinase
R (PKR) is activated by binding to double stranded RNAs (dsRNAs) produced during infection [87–90],
and potently inhibits viral protein synthesis, and thus virus replication [80].
5. HCMV Manipulation of Translation Initiation
Unlike many viruses, HCMV does not limit host translation. Instead, overall levels of protein
synthesis are maintained in HCMV-infected cells [91]. As both host and viral mRNAs rely on the
same pool of ribosomes for their translation, HCMV mRNAs must efficiently compete with host
transcripts for access to the translation machinery to ensure synthesis of viral proteins. In addition,
the virus must circumvent antiviral defenses that otherwise limit protein synthesis upon infection.
HCMV infection activates both antiviral defenses and stress response pathways, yet viral protein
synthesis and replication remain unaffected (see below). While the full spectrum of strategies employed
by HCMV to regulate host responses is beyond the scope of this review, examples of the strategies
HCMV uses to maintain viral protein synthesis by counteracting host defenses and stress responses
are described below.
5.1. HCMV Infection Increases eIF4F Abundance and Activity during Infection
As discussed above, the eIF4F complex plays a critical role in translation initiation by recruiting
the 43S PIC to the 5’ end of the mRNA. Recruitment of the eIF4F complex, particularly binding
of the eIF4E subunit to the mRNA m7G cap, is thought to be the rate-limiting step of translation
initiation [92]. Overall levels of eIF4F directly correlate with the level of protein synthesis within the cell.
The sustained eIF4F-dependent translation of host mRNAs during HCMV infection suggests that the
virus manipulates cellular signaling pathways to maintain eIF4F activity (Figure 1A). Consistent with
this idea, Walsh et al. found that HCMV infection increases the abundance of eIF4F subunits and
promotes eIF4F complex formation [91]. In addition, elevated levels of PABP stimulate eIF4F
formation during infection [93]. The increase in eIF4F levels in infected cells is important for virus
replication, as disrupting or inhibiting the eIF4F complex early during infection profoundly limits viral
replication [94–96]. Similarly, an eIF4A helicase inhibitor suppresses HCMV replication in vitro when
added at the time of infection [95]. This in part reflects the necessity for eIF4F-dependent translation
of host mRNAs during infection, as depletion of several host proteins that require eIF4F for their
expression reduced the production of progeny virus [97].
In addition to increasing the abundance of eIF4F subunits, HCMV activates signaling pathways
that stimulate eIF4F complex formation. mTORC1 activity is increased in HCMV infected cells,
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promoting eIF4F formation through phosphorylation and inactivation of the 4EBP family of
translational repressors (Figure 1A) [91,94,98]. During infection, mTORC1 activity is refractile to
cellular stresses such as AMPK activation that typically decrease its activity [99–101]. In fact HCMV
paradoxically requires increased activation of both AMPK and mTOR during infection for efficient
replication [102]. Thus HCMV uncouples mTORC1 activity from negative regulatory cues to promote
virus replication. The dichotomy of continued mTORC1 activity despite AMPK activation can be
explained, in part, by the finding that the HCMV UL38 protein (pUL38) binds and inhibits the host
TSC2 protein, preventing inhibition of mTORC1 in response to nutrient deprivation and AMPK
agonists [103]. pUL38 also stimulates mTORC1 activity in a TSC2-independent manner, although the
mechanism remains unclear (Figure 1A) [104]. Thus HCMV pUL38 severs the connection between
AMPK and mTOR signaling, allowing for eIF4F formation and maintained levels of protein synthesis.
HCMV infection also stimulates additional signaling pathways that potentially enhance
translation during infection. The PI3K signaling pathway is stimulated during infection and increases
mTORC1 activity [105,106]. Chemical inhibitors of PI3K limit HCMV replication [105], suggesting
that PI3K signaling could play a role in stimulating translation in infected cells. HCMV infection also
activates the MNK kinases [91], which phosphorylate eIF4E (Figure 1A). Phosphorylation of eIF4E
is suggested to increase the rate of translation through an unknown mechanism. Inhibitors of the
MNK kinases reduce HCMV replication [91], suggesting that MNK-dependent eIF4E phosphorylation
potentially regulates protein synthesis during infection. Infection also increases the abundance of the
critical translation elongation factor eEF2 in a UL38-dependent manner (Figure 1B). While the role of
the above signaling changes in HCMV translation has not been demonstrated, their association with
the control of translation in other contexts suggests a potential role in translation regulation during
HCMV infection.
As suggested by the multiple mechanisms HCMV employs to induce and maintain mTORC1
activity, decreased mTOR activity or expression inhibits virus replication [94–96]. Depletion of
mTOR, RICTOR or RAPTOR decreases HCMV replication, as do ATP-competitive inhibitors of mTOR
kinase activity [98,107]. When added at the time of infection, mTOR inhibitors limit viral DNA
accumulation and thus the transcription of HCMV late genes. However, mTOR inhibitors also prevent
metabolic remodeling induced by HCMV during infection, thus the effects of the inhibitors are likely
pleiotropic [108]. Although mTOR inhibitors limit virus replication when added at the start of infection,
such drugs have little effect on viral protein synthesis, the association of viral mRNAs with polysomes
or virus replication when added later in infection [96,107].
5.2. IRES Activity during HCMV Infection
Many viruses use IRES elements to ensure translation of viral mRNAs under stress conditions
that limit host protein synthesis. The only IRES-like element identified to date in the HCMV genome
is located adjacent to the UL138 open reading frame (ORF). The UL138 ORF is the most 3’ of four
ORFs encoded on a polycistronic mRNA, suggesting that cap-mediated translation initiation of UL138
would be exceedingly inefficient. The UL138 IRES-like element directs internal initiation on the
polycistronic pUL138 transcript and allows for increased UL138 protein synthesis under conditions of
cell stress [109]. While the role of the UL138 IRES during infection is unknown, it likely plays a role in
regulating HCMV latency, as pUL138 acts as a molecular switch that regulates virus reactivation [110].
Whether or not HCMV encodes additional IRES-like elements that allow for non-canonical translation
initiation events remains to be determined.
HCMV infection also stimulates the translation of at least one IRES-containing cellular mRNA
needed for virus replication. Cells induce a coordinated response to the accumulation of unfolded
proteins in the ER, aptly named the unfolded protein response (UPR). While induction of the UPR
generally suppresses protein synthesis, the translation of a subset of mRNAs involved in resolving
cell stress is selectively increased. While HCMV infection induces the UPR, downstream signaling
pathways are selectively modulated to support virus replication [111,112]. One example is the increased
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IRES-dependent translation of the ER chaperone BiP (binding immunoglobulin protein) during
infection, which likely supports HCMV replication by increasing the protein folding capacity of
the ER [113,114]. HCMV stimulates BiP mRNA translation in part by increasing the expression of the
La protein, a known ITAF for the BiP IRES [115]. Given the increase in La abundance during infection
and the wide range of cellular and viral mRNAs that La interacts with, HCMV infection may stimulate
the translation of additional IRES-containing mRNAs.
5.3. HCMV Regulation of eIF2α Kinases
HCMV infection generates cellular stresses that are potent activators of eIF2α kinases. Of the eIF2α
kinases, the role of the antiviral PKR during infection is the best characterized. PKR is activated upon
binding to double stranded RNAs (dsRNAs) generated during the early stage of HCMV infection [116].
Yet PKR activation and eIF2α phosphorylation are not observed at this time, suggesting HCMV actively
prevents PKR activation. Using a screen to identify HCMV genes that rescue growth of a vaccinia virus
mutant lacking its PKR antagonist E3L, the laboratory of Dr. Adam Geballe identified the HCMV TRS1
and IRS1 proteins (pTRS1 and pIRS1, respectively) as potent PKR antagonists [117]. Expression of
either pTRS1 or pIRS1 is necessary for HCMV infection, as infection in the absence of both proteins
results in an almost complete block to virus replication [116]. The first two thirds of TRS1 and IRS1
are encoded by the terminal repeats flanking the unique short region of the HCMV genome, and
thus the first two thirds of pTRS1 and pIRS1 are identical [118]. This common amino-terminal region
contains an unusual RNA binding domain [119], which functions to competitively inhibit PKR by
binding to dsRNA ligands [120]. Both pTRS1 and pIRS1 also contain a PKR binding domain in their
divergent C-terminal region [121]. The RNA and PKR binding domains of pTRS1 are both necessary
to rescue replication of a vaccinia virus lacking the E3L protein [119,120]. However, the physical
interaction with PKR appears to be most important for PKR inhibition during HCMV infection, as
mutation or deletion of the pTRS1 PKR binding domain results in PKR activation in the absence of
pIRS1 [122,123]. When PKR is depleted or deleted prior to infection HCMV replication is restored
in the absence of pTRS1 and pIRS1 [122,123], suggesting that a major function of pTRS1/pIRS1 is to
counteract inhibition of viral protein synthesis by PKR (Figure 1B).
Despite pTRS1/pIRS1 inhibition of PKR, phosphorylated eIF2α accumulates in infected cells
during the late stage of HCMV infection [111,124]. Mammalian cells express three additional eIF2α
kinases, PERK, HRI and GCN2 whose activation could account for the observed increase in eIF2α
phosphorylation. While the potential role of HRI and GCN2 in HCMV-induced eIF2α phosphorylation
is unknown, PERK is not the relevant eIF2α kinase as phosphorylated eIF2α accumulates during
infection of PERK-depleted cells [112]. In any case, both host and viral mRNAs are translated despite
the observed increase in eIF2α phosphorylation late in infection. It is currently unclear if eIF2α
phosphorylation no longer restricts translation initiation late in infection, or if the extent of eIF2α
phosphorylation is insufficient to suppress protein synthesis. Perhaps the increased abundance and
activity of the host PP1 and PP2A phosphatases during infection [125] in conjunction with viral
inhibitors of eIF2α kinases allow for efficient translation in the presence of multiple eIF2α stresses.
Regardless, continued protein synthesis in the face of significant cellular stress suggests that HCMV
encodes viral proteins that limit eIF2α kinase activity, or actively limit eIF2α phosphorylation in
response to virus-induced stress.
6. Unresolved Questions and Future Directions
As described above, HCMV employs a variety of strategies to counteract host defenses
and maximize the translation of viral mRNAs. However, several recent studies suggest that
our understanding of HCMV manipulation of the host translation machinery is incomplete.
One unresolved question concerns the role of the eIF4F complex in HCMV protein synthesis.
Disrupting or inhibiting the eIF4F complex at the start of infection decreases HCMV replication [94–96],
correlating with a decrease in the translation efficiency of several host mRNAs needed for progression
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through the viral lytic cycle [97]. Yet as infection progresses, viral replication becomes increasingly
resistant to mTOR inhibitors, even though these inhibitors continue to efficiently disrupt eIF4F complex
formation [107]. Despite significantly reduced eIF4F abundance, HCMV mRNAs efficiently associate
with polysomes even though the translation of several host mRNAs is simultaneously decreased [95].
How are viral mRNAs efficiently translated under eIF4F-limiting conditions? Perhaps the relatively
high abundance of HCMV transcripts with structurally simple 5’UTRs allows them to compete
efficiently for ribosomes when eIF4F is limiting. Another possibility is that a host or viral factor recruits
residual eIF4F specifically to HCMV mRNAs. This may in part explain the finding that HCMV mRNAs
as a group are more efficiently translated than host mRNAs during the later stages of infection [126].
Alternatively, an unknown host or viral factor might functionally substitute for components of the
eIF4F complex. This could be a host factor that similarly facilitates translation of cellular mRNAs
under eIF4F-limiting conditions. In any case, these results suggest that translation initiation on HCMV
mRNAs differs from that on eIF4F-dependent host mRNAs. Exploring the mechanisms underlying
this difference will likely expand our understanding of both cellular and viral translation mechanisms.
Another emerging question in the regulation of HCMV translation stems from the recent discovery
that the coding potential of the viral genome has been greatly underestimated. Ribosome profiling (next
generation sequencing of ribosome-protected mRNA fragments) of HCMV infected cells combined
with mass spectrometry revealed that HCMV encodes over 750 polypeptides [127], as compared to
previous estimates of approximately 200 protein coding regions [128,129]. How does HCMV encode
such a wide array of peptides, and what is their function? In some cases the use of a near-cognate
initiation codon drives translation from previously unrecognized ORFs, although the majority of the
novel coding regions initiate with an AUG start codon. Many of the novel peptides were less than
30 amino acids in length, and therefore may not function as proteins in the commonly understood
sense. However, short peptides encoded upstream of longer coding regions on the same mRNA can
serve regulatory roles to modulate mRNA translation in response to the cellular environment. Small
upstream open reading frames, or uORFs, are translation competent ORFs consisting of fewer than
30 codons located 5’ of a protein coding region on the same mRNA ([130,131] reviewed in [132]).
Under normal conditions ribosomes initiate translation at the first AUG codon they encounter in a
favorable sequence context (e.g., Kozak sequence [35]), and therefore translate uORFs rather than the
downstream protein coding region. However, during periods of stress that limit ternary complex
availability, uORFs can counterintuitively stimulate translation of the downstream coding region [133]
through a poorly defined mechanism. Therefore these short, translation competent HCMV ORFs could
act as translational regulators for adjacent protein coding regions, providing the virus a means to
ensure continued viral protein expression under conditions of cellular stress.
Many new coding regions were also found internal or antisense to previously annotated ORFs,
raising the question of how these novel ORFs are translated. Is each peptide-coding region contained
on its own transcript? Or might HCMV extensively utilize polycistronic mRNAs to expand its coding
capacity? Based on the relative paucity of confirmed IRES elements in herpesvirus genomes, it seems
unlikely that internal ribosome entry can explain the diversity of the viral translatome. A more likely
explanation for the diversity of viral polypeptides is that the complexity of the HCMV transcriptome
has also been underestimated. Both strands of the viral genome are extensively transcribed [134–136],
potentially explaining the presence of “antisense” coding regions in some ORFs. HCMV mRNA
splicing is also more extensive than once thought [134], and alternative transcription start site (TSS)
usage in some cases extends or truncates known reading frames [136]. Such extensive transcriptome
complexity suggests that each HCMV polypeptide may arise from cap-dependent translation of a
monocistronic mRNA, rather than through IRES-dependent translation of polycistronic messages.
A more thorough characterization of the HCMV transcriptome will therefore shed light on the
mechanisms regulating the translation of the expansive HCMV proteome.
While we know much about the control of mRNA translation during HCMV infection, much
remains to be learned. The growing list of high-resolution techniques available to study protein
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synthesis should allow for a more complete picture of regulatory events controlling both host and
viral mRNA translation during HCMV infection. Given the growing appreciation of the importance of
translation regulation in multiple disease states, this knowledge may lead to new targets for novel
therapeutics that inhibit viral protein synthesis, and thereby decrease HCMV disease.
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eIF4F eukaryotic initiation factor 4F
m7G cap 7-methyl guanosine cap
43S PIC 43S preinitiation complex
UTR untranslated region
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eEF2 eukaryotic elongation factor 2
eIF4E eukaryotic initiation factor 4E
eIF4G eukaryotic initiation factor 4G
eIF4A eukaryotic initiation factor 4A
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mTOR mammalian target of rapamycin kinase
4EBP1 eIF4E-binding protein 1
p70S6K 70 kDa ribosomal protein S6 kinase
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AKT protein kinase B
eIF2α eukaryotic initiation factor 2 alpha subunit
eIF2B eukaryotic initiation factor 2B
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ER endoplasmic reticulum
PERK PKR-like endoplasmic reticulum kinase
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PKR protein kinase R
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UPR unfolded protein response
BiP binding immunoglobulin protein
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TSS transcription start site
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